Hemp Enforcement, Modernization, and Protection Act
- Sponsor
- Rep. Griffith, H. Morgan [R-VA-9]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jan 22, 2026
Bottom line
This bill seeks to bring cannabinoid hemp products, including those containing intoxicating cannabinoids, under federal FDA regulation, establishing safety, labeling, and manufacturing standards similar to other regulated consumer products.
What it actually does
H.R. 7212, the "Hemp Enforcement, Modernization, and Protection Act," amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to establish a comprehensive regulatory framework for cannabinoid hemp products under the Food and Drug Administration (FDA). It defines various cannabinoid terms, sets standards for oral, inhalable, and topical products, mandates facility registration and product listing, and grants the FDA new enforcement powers, including mandatory recall authority.
Proponents argue
Supporters argue that the current lack of clear federal regulation for cannabinoid hemp products creates a chaotic market, poses public health risks due to inconsistent product quality and labeling, and allows for the proliferation of potentially unsafe or mislabeled goods. This bill would ensure consumer safety, provide regulatory clarity for businesses, and establish a level playing field.
Opponents contend
Critics might argue that the proposed regulations are overly burdensome for small businesses, could stifle innovation in the rapidly evolving hemp industry, or that certain provisions (e.g., age limits, specific ingredient restrictions) are too restrictive or preempt state-level efforts that are already in place. Some may also argue that the FDA is not the appropriate agency for this type of regulation, or that the thresholds for intoxicating cannabinoids are too low or too high.
The bill is moderately complex due to its technical definitions and extensive new regulatory framework, requiring a dedicated reading to grasp its full implications.
Section 3
Comprehensive Definitions for Cannabinoids and Hemp Products
This section significantly expands definitions within the FFDCA. It defines "cannabinoid" broadly to include naturally occurring and synthetic compounds, and requires the Secretary to maintain a public list. It then defines "cannabinoid hemp product" as any article containing these cannabinoids intended for human or animal use, while explicitly excluding FDA-approved drugs, biologics, devices, and certain food additives. It further defines "inhalable," "oral," and "topical" cannabinoid hemp products, and crucially, "prohibited cannabinoid product" based on content limits and types of cannabinoids. "Total intoxicating cannabinoid content" is also defined.
Supporters argue
Proponents argue these clear, comprehensive definitions are essential to establish a consistent regulatory perimeter, distinguish legal hemp products from illicit substances, and provide a basis for effective enforcement and consumer protection.
Critics contend
Critics might argue that the definitions are too broad, potentially encompassing products not intended for strict regulation, or too narrow, failing to adapt to future innovations. Concerns could also be raised about the inclusion of "synthetic means" cannabinoids, which some in the industry distinguish.
Tradeoffs
Balancing comprehensive coverage of diverse cannabinoid products with avoiding overreach or stifling innovation. Defining "intoxicating" content precisely to allow for non-intoxicating products while curbing high-potency psychoactive ones.
Section 4, inserting new Chapter X
New Regulatory Chapter for Cannabinoid Hemp Products
This section establishes a new Chapter X within the FFDCA specifically for "Cannabinoid Hemp Products." It outlines definitions pertinent to this chapter (e.g., "adverse event," "facility," "responsible person"), and details conditions under which cannabinoid hemp products are deemed "adulterated" or "misbranded." It also sets forth specific standards for oral, inhalable, and topical products, mandates a minimum age of sale, manufacturing and testing requirements, facility registration, product listing, and grants mandatory recall authority. An advisory committee is also established.
New FFDCA Chapter X, Section 1002
Criteria for Adulterated Cannabinoid Hemp Products
This section defines when a cannabinoid hemp product is considered "adulterated." This includes contamination, unsanitary conditions, unsafe packaging, exceeding total cannabinoid limits (as defined in 201(xx)), being intended for food-producing animals, containing prohibited added substances (like alcohol, caffeine, tobacco, nicotine, melatonin), unsafe food additives (for oral products), or failing to comply with specific standards for oral, inhalable, or topical products. It also includes refusal of inspection as a basis for adulteration.
New FFDCA Chapter X, Section 1003
Criteria for Misbranded Cannabinoid Hemp Products
This section defines when a cannabinoid hemp product is considered "misbranded." This includes false or misleading labeling/advertising, lack of required label information (manufacturer, quantity, "cannabinoid hemp product" statement, serving size/servings per container for oral products, ingredients, cannabinoid content, allergen disclaimers, risk disclaimers, QR code for testing results, instructions, adverse event reporting info), non-compliance with prescribed label formats, exceeding dose limits, lack of adequate directions/warnings, claims regarding body function, non-child-resistant packaging, marketing to children, or failure to register facilities or list products. It also prohibits labeling as a dietary supplement.
New FFDCA Chapter X, Section 1004
Specific Standards for Oral Cannabinoid Hemp Products
This section sets additional requirements for oral cannabinoid hemp products. It mandates that these products adhere to serving size and content limits (to be specified by regulation under Sec. 1012), and if a package contains multiple servings, they must be individually divided. Liquid containers must be single-serving or include a measuring device. It also requires prominent front-of-package labeling and allows the Secretary to prescribe standardized information panel formats and tamper-evident/child safety packaging.
New FFDCA Chapter X, Section 1005
Specific Standards for Inhalable Cannabinoid Hemp Products
This section establishes stringent requirements for inhalable cannabinoid hemp products. It prohibits pesticide residues above tolerance levels, restricts added terpenes or flavoring agents to only those naturally occurring in Cannabis sativa L. and deemed safe by the Secretary, and limits other ingredients to those explicitly permitted by the Secretary. It also restricts manufacturing solvents/extraction methods to those deemed safe. Components must not pose unreasonable risks and meet specific standards. Critically, most aerosolized products must be sold in prefilled, nonrefillable cartridges (except for whole cannabis inflorescence). It mandates prominent warning statements, specific labeling for cartridges, and pre-market notification for new and existing products.
New FFDCA Chapter X, Section 1007
Minimum Age of Sale for Cannabinoid Hemp Products
This section makes it unlawful for any retailer to sell a cannabinoid hemp product to anyone younger than 21 years of age.
New FFDCA Chapter X, Section 1008
Uniform Manufacturing and Testing Requirements
This section mandates the Secretary (FDA) to establish uniform manufacturing and testing requirements for cannabinoid hemp products, including specifications for components, contaminants, and cannabinoid content. The Secretary may recognize standards developed by third-party, audited standard-setting bodies. The FDA is also granted authority to inspect records to ensure compliance.
New FFDCA Chapter X, Section 1009
Mandatory Facility Registration and Product Listing
This section requires all facilities (domestic and foreign) engaged in manufacturing, processing, packing, importing, labeling, or holding cannabinoid hemp products for U.S. consumption to register with the Secretary (FDA). It specifies registration contents, initial registration deadlines (1 year for existing, 60 days for new), and biennial renewal. It also mandates responsible persons to submit a cannabinoid hemp product listing for each product, with specific deadlines and content requirements. The Secretary can suspend facility registrations if products pose serious adverse health consequences.
New FFDCA Chapter X, Section 1011
FDA Mandatory Recall Authority for Cannabinoid Hemp Products
This section grants the Secretary (FDA) mandatory recall authority for cannabinoid hemp products deemed adulterated or misbranded if their use or exposure will cause serious adverse health consequences or death. The FDA must first offer the responsible person an opportunity for voluntary recall. If refused or not acted upon, the Secretary can issue an order to cease distribution or recall, followed by an informal hearing. The FDA is also required to ensure public notification of recalls, including press releases and website alerts.
New FFDCA Chapter X, Section 1012
Establishment of Cannabinoid Content Thresholds
This section mandates the Secretary (FDA) to issue a rule specifying applicable thresholds for total cannabinoid content in inhalable, oral, and topical products, and for total intoxicating cannabinoid content in oral products. It sets a timeline: proposed rulemaking within 60 days of enactment and a final rule within 3 years. If the FDA fails to finalize the rule within 3 years, default thresholds are established: 10mg/serving and 50mg/package for oral products, 100mg/serving and 500mg/package for inhalable and topical products, and 5mg/serving and 30mg/package for total intoxicating cannabinoid content in oral products.
New FFDCA Chapter X, Section 1013
Establishment of Advisory Committee
This section establishes the "Cannabinoid Hemp Products Advisory Committee" to provide advice, information, and recommendations to the Secretary (FDA) on cannabinoid content limits and other matters. The committee will have 16 members, including FDA representatives, medical/scientific professionals, government officials, a public representative, a state cannabis regulator, and non-voting representatives from the Cannabis sativa L. manufacturing industry (large and small businesses) and growers. Strict conflict-of-interest rules apply to voting members. The committee must report to Congress annually.
The bill amends the definition of "dietary supplement" to explicitly exclude "cannabinoid hemp product."
Section 3, amending 21 U.S.C. 321(ff)(1)
Why it matters:This is standard legislative practice for definitional amendments, but it has significant implications for the regulatory pathway of these products.
Case for: Proponents argue this clarifies that cannabinoid hemp products are not to be regulated as dietary supplements, which have different regulatory pathways and requirements, and prevents manufacturers from attempting to market them as such without meeting the more stringent safety and labeling standards proposed in this bill.
Case against: Some in the hemp industry have advocated for cannabinoid products, particularly CBD, to be regulated as dietary supplements, arguing it's a more appropriate and less burdensome framework. This exclusion directly counters that position.
Estimated impact: Prevents a major regulatory pathway for cannabinoid products, forcing them into the new, more restrictive framework.
The bill amends the definition of "new drug" to explicitly include "a cannabinoid hemp product under paragraph (uu)." This means cannabinoid hemp products are *not* automatically considered "new drugs" that would require extensive FDA approval processes.
Section 3, amending 21 U.S.C. 321(rr)(2)
Why it matters:Standard legislative practice for definitional amendments, but crucial for the legal existence of the market.
Case for: Proponents argue this prevents all cannabinoid hemp products from being automatically classified as "new drugs," which would impose an impossible regulatory burden (requiring individual drug approvals for countless products) and effectively ban the market. It allows for a tailored regulatory approach.
Case against: Some public health advocates might argue that without the "new drug" designation, products might not undergo the rigorous safety and efficacy testing typically associated with drugs, potentially leaving consumers vulnerable.
Estimated impact: Crucial for the legal existence of a cannabinoid hemp product market outside of pharmaceutical drugs.
If the Secretary fails to finalize the rule specifying cannabinoid content thresholds within 3 years, specific default thresholds automatically take effect. These include 5mg/serving and 30mg/package for total intoxicating cannabinoid content in oral products.
Section 1012(c)
Why it matters:This is a common legislative tactic to ensure that a regulatory framework does not stall due to agency inaction, providing a clear, albeit potentially less nuanced, set of rules.
Case for: Proponents argue that these default thresholds provide regulatory certainty and prevent a vacuum if the FDA is slow to act. They ensure that some level of control over intoxicating cannabinoids is in place.
Case against: Critics might argue that these default thresholds are arbitrary or not sufficiently science-based, and could either be too permissive or too restrictive, depending on the specific cannabinoid and product type. The 3-year delay for a final rule is also a concern.
Estimated impact: Could significantly shape the market for oral cannabinoid hemp products if the FDA misses its deadline, potentially forcing product reformulation or removal.